Capstone Investment Advisors, LLC Neurocrine Biosciences Inc Transaction History

Capstone Investment Advisors, LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 01, 2024	BUY	$130.4 - $143.74 $424,843 - $468,304	3,258 Added 136.09%	5,652 $779,000
Q4 2023 Feb 12, 2024	SELL	$106.07 - $132.76 $101,190 - $126,653	-954 Reduced 28.49%	2,394 $315,000
Q3 2023 Nov 13, 2023	BUY	$94.02 - $117.1 $314,778 - $392,050	3,348 New	3,348 $376,000
Q1 2018 May 15, 2018	SELL	$75.88 - $92.43 $490,867 - $597,929	-6,469 Closed	0 $0
Q4 2017 Feb 14, 2018	BUY	$58.53 - $77.59 $378,630 - $501,929	6,469	6,469 $501,000

625

94.2M

632K

621K

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $12B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

Get notified when there are updates to the investment portfolio of Capstone Investment Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Capstone Investment Advisors, LLC with notifications on news.